Joined the holders in CBF this morning. Looks like a recovery going on here and I here whispers well speculation of new contract wins. The company seems to be moving away from DNA and focusing on protein and virus production and they seem to be far more focussed.

The company have restructured their sales and marketing team and appear to be more aggresive in their actions.

Fixed and variable costs have also been attacked and the company is working from a lower cost base. The companys order book is higher than it as been for a while and I beleive quarterly profit will be achieved.

Chart also looks strong and shows a break up.

Pointers To Recovery.

From last results 11th Jan.

Sales improvement in the second half of the financial year due to switch
from DNA to proteins and virus.



Restructuring of sales and marketing to address US market.



Restructuring of the Oxford and Keele facilities.



Broadening of customer base - 12 new customers in 2004.



The 4.8m Oxford Facility completed on time and to budget.



Contracted business for financial year 2005 stands at 2.7m.



Financial:


Revenue: H2 2004 up 30% to 2.0m compared with H1 2004 1.5m
FY 2004 down 42% to 3.5m (FY 2003: 6.0m)

Gross margin: H2 2004 49% compared with H1 2004 39%
FY 2004 45% (FY 2003: 57%)

Loss before tax: H2 2004 reduced by 17% to 1.03m compared with H1 2004 1.24m
FY 2004 2.27m (FY 2003: 0.82m profit)

Cash at bank: Sept 2004 3.2m compared with Mar 2004 3.8m (FY 2003: 7.3m)

Loss per share: FY 2004 12.3p (FY 2003: 6.9p earnings)

Director Speak

Commenting on the results, Peter Fothergill, Executive Chairman said:

'Our second half improvement and the current position of our order book are
significant achievements. Management moved rapidly during the year to focus
sales and marketing in the US and from DNA to virus and protein production. This
was no mean feat and we are cautiously optimistic for the future.'

Company Outlook Statement.

Management is actively seeking to broaden the customerbase particularly in the US biotechnology clusters and is examining ways toexpand the service offering including later stage manufacture and there by developing longer-term relationships which can reduce the impact of the high levels of clinical trials failure. These initiatives are already beginning to gain traction with contracted business currently 2.7 million for the financial year 2005 ('2005'), with 52% from North America. If this improvement continues Cobra will recover value for its shareholders.

Fundies.

Presently loss making but looks like the corner has been turned. Awaiting next trading update/results.

Beta.

Fairly High.

Conclusion

Highly Speculative, but the rewards if recovery does take place could be very rewarding.



cheers GF.

Got out at 53, just as well.

MS

Its been a cracking day for this one.

cheers GF.

Mickey jumped ship to quick he should of had more faith.
DB66

Any share that has EK in gets me spooked. Took my money and topped up MMG. Now tell me I made a mistake, I don't think so. This share has a real bad track record. OK things may have changed. If it really does start to happen I can always get back in.

LOL and have a good week end.

MS

Fair enough, have a good weekend yourself and lets all have a drink or two for MMG and Goldfinger and roll on Monday.
DB66

RNS Number:0853K
Cobra Bio-Manufacturing PLC
23 March 2005


For Immediate Release 23 March 2005


COBRA BIOMANUFACTURING PLC

PRE-CLINICAL DATA SUPPORTS POTENTIAL OF COBRA'S PROPIETARY ORT-VAC ORAL
BACTERIAL VACCINE

Keele, UK: Cobra Biomanufacturing plc (AIM: CBF), the international manufacturer
of biopharmaceuticals, today announces the results of a five year research
collaboration with the UK Ministry of Defence agency dstl, (Defence Science and
Technology Laboratory), Porton Down, UK, on the development of an improved
approach to oral vaccination that avoids the risks of using antibiotics or
antibiotic-resistance genes.

Comparison of the ORT-VAC system with conventional bacteria vaccine strains show
that, post administration, the ORT VAC product is stable and the conventional
strains highly unstable. In other experiments reported in the same paper, using
a rigorous plague challenge model in rodents, proof-of-principle results
published today show that a single oral dose vaccine achieved a high level of
immunity against plague.

The results of this research collaboration are published today in the
prestigious peer reviewed journal Infection and Immunity (Volume 73, Issue: 4
Page 2005), published by the American Society of Microbiology. http://
iai.asm.org/cgi/content/abstract/73/4/2005

Commenting on the results, Dr David Thatcher, Cobra's CEO, said:

"Cobra's scientists are renowned for their innovative approaches. Results from
this publication could represent a breakthrough in vaccine strain development as
they clearly demonstrate that ORT-VAC technology will allow the production and
oral delivery of stable strains carrying a high number of copies of the vaccine
gene per cell and therefore ORT-VAC strains are likely to have increased potency
compared with conventional strains.

The results also show that approaches to the development of high potency oral
vaccine strains, using conventional molecular biology, lead to strains which
rapidly lose their component antigen genes after administration and therefore
are potentially less effective compared with the fully stabilised ORT-VAC
vaccines. ORT-VAC approach avoids use of live bacteria which are antibiotic
resistant and carry a serious potential of generating antibiotic resistant
infection."

The ORT-VAC technology allows easy oral administration and cost effective
manufacture of vaccines. It is readily applicable to convert any suitable
bacteria strain to an antibiotic-free ORT strain for DNA and recombinant protein
vaccine delivery in humans. Recombinant protein vaccines are becoming
increasingly important as a prophylaxis and as a therapy. ORT-VAC vaccines will
have applications in cancer, HIV/Aids and tuberculosis as well as newly emerging
diseases, such as avian flu. It will also have utility against diseases such as
anthrax posed by the threat of bioterrorism.

For further information please contact:

David Thatcher Cobra Biomanufacturing + 44 (0) 1782 714181
Chief Executive Officer

Mark Court/Rebecca Skye Dietrich Buchanan Communications + 44 (0) 207 466 5000

Eileen Paul Northbank Communications + 44 (0) 1260 296500


Notes To Editors:

About Cobra Biomanufacturing Plc

Cobra Biomanufacturing Plc is a leading international manufacturer of
biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides
innovative manufacturing solutions to the biopharmaceutical industry covering
DNA, virus, cellular therapeutics and recombinant protein products.

Cobra was the first company to develop and gain GMP (Good Manufacturing
Practice) standard DNA manufacture in Europe, with specific expertise in DNA
medicines. A range of unique, patented technologies, underpins this revenue
generating business.

Cobra floated on the Alternative Investment Market of the London Stock Exchange
in June 2002 raising #7 million and raised a further #5.2 million in May 2003 in
order to further expand capacity in Oxford UK.

www.cobrabio.com

ORT(R) Technology is a way of creating totally stable genetically engineered
strains of micro-organisms without the use of antibiotics or antibiotic genes.
Other technologies rely on either integrating the synthetic gene(s) into the
bacterial chromosome or using antibiotics and antibiotic resistance genes to
amplify replicating mini-chromosomes (called plasmids) containing the new genes.
In the vaccine field it has been known for 10 years that the former approach
leads to poor strain productivity and the latter to strain instability. Use of
antibiotics also creates the risk of passing on the antibiotic resistance genes
to pathogens in the environment. Such events have occurred naturally to create
MRSA super bug strains so ORT(R) strains are inherently safer for patients.
ORT(R) technology avoids these problems.

Live Oral Vaccines are vaccines where the active agent is a live organism and is
taken orally. Live vaccines have been based on attenuated strains of the
disease-causing organism and historically this approach has been particularly
effective in inducing protection against disease (e.g. BCG for tuberculosis).
Attenuated live strains of Adenovirus and Salmonella have been used as oral
vaccines against respectively respiratory illness and typhoid caused by the
virulent parental strains. The advent of genetic engineering means that bacteria
such as Salmonella can be genetically modified to carry new traits that can
protect against a chosen disease not only diseases of the gut.

ORT-VAC Technology harnesses the advantages of conventional genetic engineering
with the safer ORT(R) strain stabilisation technology. ORT-VAC allows rapid and
simple construction of bacterial vaccine strains, capable of expressing massive
quantities of synthetic antigenic proteins that can lead to protection against
disease without the fear of creating antibiotic resistant strains which might be
difficult to manage clinically. ORT-VAC technology can potentially be used to
protect both against common infectious diseases such as meningitis, new diseases
such as Avian Flu, old diseases posing a new threat such as those which could be
used by terrorists and also cancer.

Statements contained within this press release may contain forward-looking
comments which involve risks and uncertainties that may cause actual results to
vary from those contained in the forward-looking statements. In some cases, you
can identify such forward-looking statements by terminology such as 'may', '
will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', '
estimates', 'predicts', 'potential', or 'continue'. Predictions and
forward-looking references in this press release are subject to the satisfactory
progress of research, which is, by nature, unpredictable. Forward projections
reflect management's best estimates based on information available at the time
of issue.


This information is provided by RNS
The company news service from the London Stock Exchange

Nice to see this on the move Mickey had me worried when he said EK was in this.Thanks for the post Alder looks promising.
DB66

Evils in it LONG not short.

cheers GF.

Thanks Goldfinger, in that case welcome aboard Evil.
db66

a snipit from the AFX

ORT-VAC vaccines will have applications in cancer, HIV/Aids and tuberculosis as well as newly emerging diseases, such as avian flu, Cobra added, and will will also have utility against diseases such as anthrax posed by the threat of bioterrorism.

looking very good

Ping!

going up strongly.

GREAT NEWS! It will be the next MMG

UK smallcap opening - Cobra Bio up on vaccine press comment
AFX


LONDON (AFX) - Shares in Cobra Bio-Manufacturing, firm yesterday following the publication of a positive study, moved up 6-1/2 pence more to 64-1/2 after press comment suggesting that major drugs firms will now be knocking on the door.

The study showed that pre-clinical data supports the potential of the biopharmaceutical maker's proprietary Ort-Vac oral bacterial vaccine.

positive stuff - should see 100p again this year. story taking shape and prospects improving all the time.

Superb news.

cheers GF.

hlyeo98 nice one,good rise again today and hopefully over the weekend we should see some more press coverage.i think todays article was in the Mail.

Thank you, Alderleyedge, with MMG and CBF and VML, they are winners. Have a good Easter, Alderley.

hyleo have a good one yourself,
here is the mail article

ANALYSTS reckon that major drugs firms will now be knocking on the door of
Cobra Biomanufacturing.It follows the publication of a study showing that pre clinical data supports the potential of the biopharmaceutical makers proprietary Ort-Vac oralbacterial vaccine.Dealers also expect the trading statement on 7th April to confirm that Cobra is now in the best of health.
Shares rose 5.75 to 58p

CBF a company with great potential...

23 March 2005
Pre-clinical Data Supports Potential of Cobra's Proprietary ORT-VAC Oral Bacterial Vaccine
Cobra Biomanufacturing plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces the results of a five year research collaboration with the UK Ministry of Defence agency dstl, (Defence Science and Technology Laboratory), Porton Down, UK, on the development of an improved approach to oral vaccination that avoids the risks of using antibiotics or antibiotic-resistance genes.
Comparison of the ORT-VAC system with conventional bacteria vaccine strains show that, post administration, the ORT VAC product is stable and the conventional strains highly unstable. In other experiments reported in the same paper, using a rigorous plague challenge model in rodents, proof-of-principle results published today show that a single oral dose vaccine achieved a high level of immunity against plague.
The results of this research collaboration are published today in the prestigious peer reviewed journal Infection and Immunity (Volume 73, Issue: 4 Page 2005), published by the American Society of Microbiology [http://iai.asm.org/cgi/content/abstract /73/4/2005]
Commenting on the results, Dr David Thatcher, Cobras CEO, said: Cobras scientists are renowned for their innovative approaches. Results from this publication could represent a breakthrough in vaccine strain development as they clearly demonstrate that ORT-VAC technology will allow the production and oral delivery of stable strains carrying a high number of copies of the vaccine gene per cell and therefore ORT-VAC strains are likely to have increased potency compared with conventional strains.
Continuing Dr Thatcher says: The results also show that approaches to the development of high potency oral vaccine strains, using conventional molecular biology, lead to strains which rapidly lose their component antigen genes after administration and therefore are potentially less effective compared with the fully stabilised ORT-VAC vaccines. ORT-VAC approach avoids use of live bacteria which are antibiotic resistant and carry a serious potential of generating antibiotic resistant infection.
The ORT-VAC technology allows easy oral administration and cost effective manufacture of vaccines. It is readily applicable to convert any suitable bacteria strain to an antibioticfree ORT strain for DNA and recombinant protein vaccine delivery in humans. Recombinant protein vaccines are becoming increasingly important as a prophylaxis and as a therapy. ORT-VAC vaccines will have applications in cancer, HIV/Aids and tuberculosis as well as newly emerging diseases, such as avian flu. It will also have utility against diseases such as anthrax posed by the threat of bioterrorism.


2 March 2005
Cobra signs agreement with Hawaii Biotech Inc to manufacture two novel protein vaccines against Dengue fever and West Nile disease for US clinical trials
Cobra Biomanufacturing Plc (London Stock Exchange AIM), has announced that it has signed an agreement with Hawaii Biotech, USA, to manufacture and supply material for clinical trials of vaccines against Dengue fever and West Nile disease. The financial terms and conditions of the agreement were not disclosed.
Hawaii Biotechs vaccine technology is based on the production of proprietary genetically engineered antigens (proteins) that produce immune responses equivalent to or better than traditional live or inactivated virus approaches. The Dengue vaccine product consists of an adjuvant and five viral proteins which have been cloned and expressed in insect cells. The West Nile vaccine product consists of a single recombinant protein and adjuvant. The vaccines potentially have a significantly improved safety profile compared to traditional approaches.
Dengue fever and West Nile disease are growing problems in North America. Dengue fever is expanding globally with an estimated 50 million to 100 million cases of Dengue worldwide annually, with more than 20,000 deaths. Caused by a virus that is carried by mosquitoes it produces severe flu-like symptoms that can lead to a life threatening haemorrhagic fever. Unknown in North America until 1999, the West Nile virus is now permanently established throughout this territory. A significant cause of human illness in the US from 2002, its most serious manifestation is fatal encephalitis (inflammation of the brain). West Nile virus also causes disease in numerous wild and domestic animal species.
Commenting on the agreement, Dr David Thatcher, CEO Cobra said: "This is a significant program for Cobra and we are thrilled to have been selected by Hawaii Biotech. Todays announcement is a valuable endorsement of our ability to manufacture protein vaccine products for US clinical trials and demonstrates our continued ability to penetrate the North American biopharmaceutical market."
David G. Watumull, President and CEO, Hawaii Biotech added: "Hawaii Biotech,Inc is pleased to enter this collaboration with Cobra Biomanufacturing Plc. for the cGMP manufacture of our Dengue and West Nile recombinant subunit vaccine candidates. This is an important step in the preclinical development of these vaccines and critical to the successful launch of our anticipated Phase 1 clinical trials for both Dengue and West Nile vaccines in 2006. We have been impressed by the experience Cobra brings to the table and look forward to a mutually beneficial collaboration."


25 February 2005
Cobra signs long term deal with Neovacs SA to supply Phase I clinical trial material for a novel protein active immunization therapy-TNFa Kinoid
Cobra Biomanufacturing Plc (AIM:CBF.L), the international manufacturer of biopharmaceuticals, announces today that it has signed a long term manufacturing agreement with Neovacs SA to supply clinical trial material for a protein biopharmaceutical, TNFa Kinoid. This novel active immunization therapy against the human cytokine, Tumour Necrosis Factor a (TNFa), will be tested for its efficacy in auto-immune and inflammatory diseases. The terms and value of the agreement were not disclosed.
Overproduction of protein cytokines, such as TNFa, is the cause of many inflammatory diseases. Neovacs Kinoid technology involves inactivating cytokines and conjugating them to a carrier. The resulting cytokine protein complex (Kinoid) serves as an active immunization therapy that induces a natural and potent antibody response by the patients immune system. This enables the harmful cytokines to be neutralised and the disease treated. In addition to TNFa Kinoid, Neovacs is developing other active immunization therapies against numerous human cytokines to treat a range of diseases.
Alain Huriez, CEO of Neovacs, commented: We were impressed with Cobras expertise and track record in protein process development. We feel confident that Cobra will deliver us quality Kinoids on schedule for our Phase I clinical trials.
David Thatcher, CEO of Cobra, said: We are pleased to be selected by Neovacs to produce this novel cytokine protein complex for European clinical trails. This long term agreement recognises Cobras expertise in producing emerging protein therapies and vaccines.


18 February 2005
New trial of HIV/AIDS vaccine incorporates Cobra technology
Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces that its proprietary DNA system has begun clinical evaluation as part of a new HIV/AIDS vaccine clinical trial funded by the European Union.
The Phase I trial is conducted by a consortium (Eurovacc) of organisations including Cobra and will be carried out initially in the UK and Switzerland. The AIDS vaccine involves an initial injection with DNA, designed with the participation of Cobra and using Cobras proprietary ORT DNA backbone and manufacturing technology.
The initial dose is then followed by a booster dose with a genetically engineered pox virus. The DNA-HIV-C vaccine was developed by Professors Hans Wolf and Ralf Wagner at the University of Regensburg based on a representative Chinese subtype C isolate CN54 jointly developed with Professor Yiming Shao from the CDC Beijing, and is designed to combat strains of HIV/AIDS prevalent in Asia and sub-Saharan Africa.

moving along nicely again today!